LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Fate Therapeutics Inc

Fechado

SetorSaúde

1.6 18.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.32

Máximo

1.67

Indicadores-chave

By Trading Economics

Rendimento

15M

-38M

Vendas

-231K

1.6M

EPS

-0.32

Margem de lucro

-2,309.454

Funcionários

181

EBITDA

4.3M

-38M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+237.5% upside

Dividendos

By Dow Jones

Próximos Ganhos

11 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

26M

149M

Abertura anterior

-16.92

Fecho anterior

1.6

Sentimento de Notícias

By Acuity

75%

25%

353 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Fate Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de jun. de 2025, 14:31 UTC

Ganhos

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 19:36 UTC

Conversa de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 de jun. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 de jun. de 2025, 18:46 UTC

Conversa de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 de jun. de 2025, 18:02 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 de jun. de 2025, 16:35 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:34 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:21 UTC

Conversa de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

6 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 de jun. de 2025, 15:53 UTC

Conversa de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 15:33 UTC

Conversa de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 de jun. de 2025, 15:16 UTC

Conversa de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 de jun. de 2025, 15:05 UTC

Conversa de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 de jun. de 2025, 14:35 UTC

Conversa de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 de jun. de 2025, 14:15 UTC

Conversa de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 de jun. de 2025, 14:12 UTC

Ganhos

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 de jun. de 2025, 14:09 UTC

Ganhos

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparação entre Pares

Variação de preço

Fate Therapeutics Inc Previsão

Preço-alvo

By TipRanks

237.5% parte superior

Previsão para 12 meses

Média 5.4 USD  237.5%

Máximo 12 USD

Mínimo 2 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.9101 / 1.14Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

353 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.